Christiana Stamoulis Sells 9,039 Shares of Hologic, Inc. (NASDAQ:HOLX) Stock

Hologic, Inc. (NASDAQ:HOLX) Director Christiana Stamoulis sold 9,039 shares of the business’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Hologic Stock Performance

Shares of HOLX stock opened at $78.11 on Monday. The business’s fifty day simple moving average is $74.26 and its 200-day simple moving average is $74.82. The company has a market cap of $18.23 billion, a PE ratio of 39.85, a PEG ratio of 2.60 and a beta of 0.99. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $82.45.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the firm earned $1.06 EPS. The firm’s revenue was down .8% on a year-over-year basis. Analysts expect that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hologic

Hedge funds have recently made changes to their positions in the company. Norges Bank acquired a new position in shares of Hologic in the 4th quarter valued at $217,529,000. Nordea Investment Management AB boosted its stake in shares of Hologic by 1.3% during the 1st quarter. Nordea Investment Management AB now owns 1,507,743 shares of the medical equipment provider’s stock worth $116,797,000 after acquiring an additional 19,680 shares in the last quarter. Pinebridge Investments L.P. boosted its stake in shares of Hologic by 39.8% during the 4th quarter. Pinebridge Investments L.P. now owns 397,251 shares of the medical equipment provider’s stock worth $28,384,000 after acquiring an additional 113,050 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of Hologic by 18.3% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,184,427 shares of the medical equipment provider’s stock worth $170,297,000 after purchasing an additional 338,212 shares during the last quarter. Finally, Mediolanum International Funds Ltd acquired a new position in shares of Hologic during the 1st quarter worth about $1,793,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HOLX has been the subject of a number of recent research reports. Evercore ISI reduced their price objective on shares of Hologic from $78.00 to $76.00 and set an “in-line” rating for the company in a research note on Tuesday, July 2nd. Stephens initiated coverage on shares of Hologic in a research note on Thursday, June 27th. They issued an “overweight” rating and a $87.00 price objective for the company. JPMorgan Chase & Co. boosted their price objective on shares of Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a research note on Friday, May 3rd. Argus boosted their price objective on shares of Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Friday, May 3rd. Five analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $85.55.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.